Cardiovascular and renal morbidity in Takayasu arteritis: a population-based retrospective cohort study from UK.

Goel, Ruchika, Chandan, Joht Singh, Thayakaran, Rasiah, Adderley, Nicola J, Nirantharakumar, Krishnarajah and Harper, Lorraine (2020) Cardiovascular and renal morbidity in Takayasu arteritis: a population-based retrospective cohort study from UK. Arthritis & rheumatology (Hoboken, N.J.). ISSN 2326-5205. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

Full text not available from this repository.
Official URL: https://onlinelibrary.wiley.com/doi/10.1002/art.41...

Abstract

Cardiovascular disease (CVD) is a major complication and cause of mortality in Takayasu arteritis (TA). The frequency of cardiovascular, cerebrovascular and renal morbidity or risk of death in TA is unknown in the UK. Population-based controlled studies are lacking in this area.

METHODS

Yearly cohort and cross-sectional studies were performed from 2000 to 2017 to estimate annual incidence rates and prevalence of TA respectively. An open retrospective matched cohort study was conducted to estimate risk of hypertension, diabetes, cardiovascular morbidity, chronic kidney disease (CKD) and all-cause mortality in TA, using a UK primary care database (IQVIA Medical Research Data). Risk (adjusted hazard ratio, aHR) of studied co-morbidities in TA compared to age and sex-matched controls was estimated. Changes in medication prescription were examined over time in both groups.

RESULTS

Overall, 142 patients with TA (median (IQR) age 53.4 (33.8-70.7) years) and 1371 matched controls were included. The annual incidence and prevalence of TA was 0.8/million and 7.5/million respectively. All-cause mortality was increased in TA (aHR 1.88, 95% CI 1.29-2.76). Patients with TA had higher risk of developing ischaemic heart disease, stroke/TIA, combined CVD and peripheral vascular disease than controls, but not hypertension, CKD, heart failure or diabetes during follow up. Only 50% of patients with TA requiring secondary CVD prevention were prescribed statins or anti-platelets within one year after study entry.

CONCLUSION

Cardiovascular morbidity was increased in patients with TA attending primary care services in the UK. Treatment with statins and anti-platelets in these patients was suboptimal.

Item Type: Article
Additional Information: This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects: WG Cardiovascular system. Cardiology
WJ Urogenital system. Urology
Divisions: Clinical Support > Immunology
Planned IP Care > Urology
Related URLs:
Depositing User: Mrs Yolande Brookes
Date Deposited: 23 Oct 2020 13:37
Last Modified: 23 Oct 2020 13:37
URI: http://www.repository.uhblibrary.co.uk/id/eprint/3572

Actions (login required)

View Item View Item